{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02974647",
            "orgStudyIdInfo": {
                "id": "16-1542"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma",
            "officialTitle": "Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-ruxolitinib-in-relapsed-or-refractory-t-or-nk-cell-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-11"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-11-23",
            "studyFirstSubmitQcDate": "2016-11-25",
            "studyFirstPostDateStruct": {
                "date": "2016-11-28",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-04-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Cornell University",
                    "class": "OTHER"
                },
                {
                    "name": "Dana-Farber Cancer Institute",
                    "class": "OTHER"
                },
                {
                    "name": "Thomas Jefferson University",
                    "class": "OTHER"
                }
            ]
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoma"
            ],
            "keywords": [
                "Ruxolitinib",
                "T or NK Cell",
                "Relapsed",
                "Refractory"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 82,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "rel/ref PTCLtumors are known to contain mutations associ",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.",
                    "interventionNames": [
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "with rel/ref PTCL with functional evidence of JAK/STAT",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.",
                    "interventionNames": [
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "with rel/ref PTCL who do not meet criteria for cohort 1 or 2.",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.",
                    "interventionNames": [
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Rare sub-type expansion cohort: T-PLL and T-LGL & any T-Cell/NK Lymphoma with JAK fusion mutations.",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.",
                    "interventionNames": [
                        "Drug: Ruxolitinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "armGroupLabels": [
                        "Rare sub-type expansion cohort: T-PLL and T-LGL & any T-Cell/NK Lymphoma with JAK fusion mutations.",
                        "rel/ref PTCLtumors are known to contain mutations associ",
                        "with rel/ref PTCL who do not meet criteria for cohort 1 or 2.",
                        "with rel/ref PTCL with functional evidence of JAK/STAT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "disease control rate",
                    "description": "defined as the combination of complete response (CR), partial response (PR) and stable disease (SD). The reason we use this definition instead of the more conventional partial/complete response rate is twofold.",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL, patients with stage IB disease or greater are eligible.\n* Relapse or refractory disease after at least 1 systemic therapy except for T-PLL where untreated patients may be allowed after discussion with P.I.\n* Age \u2265 18\n* ECOG \u2264 2\n* Measurable disease defined by:\n\n  * Lugano Classification for systemic lymphoma or\n  * Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or\n  * mSWAT \\> 0 or Sezary count \u2265 1000 cells/\u03bcL for CTCL\n* Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued at least 2 weeks prior to treatment.\n\n  * Glucocorticoids aimed at controlling lymphoma-related symptoms are allowed as long as they are tapered down to 20mg or less by the time of ruxolitiib initiation\n  * Topical steroids for CTCL are permitted\n  * See section 6.2 Subject Exclusion Criteria for guideline regarding adjuvant and maintenance therapy for prior malignancy\n* Patients must meet the following lab criteria:\n\n  * ANC \u2265 1.0/mm\\^3 or ANC \\>/= 0.5/mm\\^3 (if patient has baseline neutropenia due to lymphoma), platelets \u2265 100 x 10\\^9/L or \u2265 50 x 10\\^9/L (if related to lymphoma), Hgb \u2265 8g/dL\n  * Patients with LGL or T-PLL are not required to meet a minimum ANC or hemoglobin value for eligibility\n  * Total bilirubin \u2264 1.5 x upper limit of normal (ULN) or; \u2264 3 x ULN if documented hepatic involvement with lymphoma, or \u2264 5 x ULN if history of Gilbert's ; AST and ALT \u2264 3 x ULN; \u2264 5 x ULN if due to lymphoma involvement\n  * Creatinine clearance \u2265 30 mL/min; creatinine clearance of 15-29 mL/min will be allowed as long as baseline platelets are \u2265 150 x 10\\^9/L\n* For patients with positive hepatitis B core antibody or surface antigen, hepatitis B PCR must be negative and prophylaxis with entecavir or equivalent is required.\n* Patients with HIV are allowed provided that they are on anti-retroviral treatment with no active infections.\n\nExclusion Criteria:\n\n* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.\n* Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, uncontrolled diabetes, clinically significant pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* ECOG performance status \\>2\n* Prior therapy with ruxolitinib\n* Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma)\n\n  * Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator\n  * Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK principal Investigator\n* Women of reproductive potential\u2020 must have a negative Serum \u00df human chorionic gonadotropin (\u00df-HCG) pregnancy test.\n\n  * A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alison Moskowitz, MD",
                    "role": "CONTACT",
                    "phone": "212-639-4839"
                },
                {
                    "name": "Steven Horwitz, MD",
                    "role": "CONTACT",
                    "phone": "212-639-3045"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alison Moskowitz, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Miami",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Northwestern Medicine (Data collection and specimen analysis)",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jaehyuk Choi, MD, PhD",
                            "role": "CONTACT",
                            "phone": "312-695-8106"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Basking Ridge",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (All Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Commack",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        },
                        {
                            "name": "Steven Horwitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3045"
                        },
                        {
                            "name": "Allison Moskowitz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Weill Cornell Medical College",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (All Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Uniondale",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alison Moskowitz, MD",
                            "role": "CONTACT",
                            "phone": "212-639-4839"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70038,
                        "lon": -73.59291
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34653242",
                    "type": "DERIVED",
                    "citation": "Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "https://www.mskcc.org/"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}